Computer-aided detection (CAD) software developer iCAD is showcasing its Breast Health Solutions suite, including the expanded ProFound AI platform, at RSNA 2019 in Chicago.
ProFound AI for digital breast tomosynthesis (DBT) is the first artificial intelligence (AI) software for DBT to be cleared by the U.S. Food and Drug Administration, according to iCAD. The company will also feature software for 2D mammography and breast density.
In addition, iCAD will discuss plans for the future, including software that lets clinicians consider patients' prior images and prospective breast cancer risk assessment over time.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
